|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2006
Outcomes and markers in the assessment of chronic obstructive pulmonary disease
1 Respiratory Medicine, St. George's, University of London, London, UK, 2 Servei de Pneumologia, Hospital Universitari Son Dureta, Fundació Caubet-Cimera, Palma de Mallorca, Spain.
CORRESPONDENCE: P. W. Jones, Respiratory Medicine, St. George's, University of London, Cranmer Terrace, London, SW17 0RE, UK. Fax: 44 208725955. E-mail: pjones{at}sgul.ac.uk
Keywords: Biological marker, chronic obstructive pulmonary disease, forced expiratory volume, physiological marker, symptomatic marker, validation
Received: December 18, 2004
Accepted November 2, 2005
The clinical presentation of chronic obstructive pulmonary disease (COPD) is highly variable, reflecting the interaction of a complex range of pathological changes including both pulmonary and systemic effects.
The consequences of COPD experienced by the patient (i.e. its outcomes) include: symptoms, weight loss, exercise intolerance, exacerbations, health-related quality of life, health resource use and death. No single measure can reflect the variety of pathological effects or adequately describe the nature or severity of COPD.
Currently, there are few validated markers for assessing COPD and evaluating the effectiveness of treatment. The forced expiratory volume in one second has been used as a global marker of COPD, but it does not fully reflect the burden of COPD on patients. New markers are needed to better characterise the full clinical spectrum of the disease and to guide the development and assessment of new and more effective therapies.
This article considers the distinction between outcomes and markers, the various ways in which markers are used and the need for new markers in the management of chronic obstructive pulmonary disease. The process of marker selection and validation is reviewed and potential new biological, physiological and symptomatic markers for chronic obstructive pulmonary disease are assessed.
This article has been cited by other articles:
|
|
 |
|
  A. Lacoma, C. Prat, F. Andreo, and J. Dominguez Biomarkers in the management of COPD Eur. Respir. Rev., June 1, 2009; 18(112): 96 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jenkins and R. Rodriguez-Roisin Quality of life, stage severity and COPD Eur. Respir. J., May 1, 2009; 33(5): 953 - 955. [Full Text] [PDF]
|
|
|
|
 |
|
 D R Taylor and I D Pavord Biomarkers in the assessment and management of airways diseases Postgrad. Med. J., December 1, 2008; 84(998): 628 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M P Swanney, G Ruppel, P L Enright, O F Pedersen, R O Crapo, M R Miller, R L Jensen, E Falaschetti, J P Schouten, J L Hankinson, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction Thorax, December 1, 2008; 63(12): 1046 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Luisetti, S. Ma, P. Iadarola, P. J. Stone, S. Viglio, B. Casado, Y. Y. Lin, G. L. Snider, and G. M. Turino Desmosine as a biomarker of elastin degradation in COPD: current status and future directions Eur. Respir. J., November 1, 2008; 32(5): 1146 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. W. Jones Symptom Measurement Chest, August 1, 2008; 134(2): 226 - 227. [Full Text] [PDF]
|
|
|
|
|
|
N. Roche, F. Dalmay, T. Perez, C. Kuntz, A. Vergnenegre, F. Neukirch, J-P. Giordanella, and G. Huchon Impact of chronic airflow obstruction in a working population Eur. Respir. J., June 1, 2008; 31(6): 1227 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dahl Biomarkers for Chronic Obstructive Pulmonary Disease: Surfactant Protein D and C-Reactive Protein Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1177 - 1178. [Full Text] [PDF]
|
|
|
|
|
|
J. P. de Torres, V. Pinto-Plata, C. Casanova, H. Mullerova, E. Cordoba-Lanus, M. Muros de Fuentes, A. Aguirre-Jaime, and B. R. Celli C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD Chest, June 1, 2008; 133(6): 1336 - 1343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jones and T. Higenbottam Quantifying of Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: Adaptations to the Definition to Allow Quantification Proceedings of the ATS, December 1, 2007; 4(8): 597 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mahler and G. J. Criner Assessment Tools for Chronic Obstructive Pulmonary Disease: Do Newer Metrics Allow For Disease Modification? Proceedings of the ATS, October 1, 2007; 4(7): 507 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mahler, L. A. Waterman, J. Ward, C. McCusker, R. ZuWallack, and J. C. Baird Validity and Responsiveness of the Self-Administered Computerized Versions of the Baseline and Transition Dyspnea Indexes Chest, October 1, 2007; 132(4): 1283 - 1290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Roche Where current pharmacological therapies fall short in COPD: symptom control is not enough Eur. Respir. Rev., September 1, 2007; 16(105): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. F. Rabe Guidelines for Chronic Obstructive Pulmonary Disease Treatment and Issues of Implementation Proceedings of the ATS, September 1, 2006; 3(7): 641 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Fabbri, F. Luppi, B. Beghe, and K. F. Rabe Update in chronic obstructive pulmonary disease 2005. Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1056 - 1065. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |